Growth Metrics

Pfizer (PFE) Income from Non-Controlling Interests (2016 - 2026)

Pfizer has reported Income from Non-Controlling Interests over the past 18 years, most recently at $8.0 million for Q1 2026.

  • Quarterly Income from Non-Controlling Interests rose 33.33% to $8.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $43.0 million through Mar 2026, up 48.28% year-over-year, with the annual reading at $41.0 million for FY2025, 32.26% up from the prior year.
  • Income from Non-Controlling Interests was $8.0 million for Q1 2026 at Pfizer, roughly flat from $8.0 million in the prior quarter.
  • Over five years, Income from Non-Controlling Interests peaked at $18.0 million in Q2 2025 and troughed at $6.0 million in Q2 2022.
  • The 5-year median for Income from Non-Controlling Interests is $8.0 million (2024), against an average of $9.2 million.
  • Year-over-year, Income from Non-Controlling Interests crashed 76.92% in 2022 and then skyrocketed 157.14% in 2025.
  • A 5-year view of Income from Non-Controlling Interests shows it stood at $15.0 million in 2022, then tumbled by 40.0% to $9.0 million in 2023, then fell by 11.11% to $8.0 million in 2024, then changed by 0.0% to $8.0 million in 2025, then changed by 0.0% to $8.0 million in 2026.
  • Per Business Quant, the three most recent readings for PFE's Income from Non-Controlling Interests are $8.0 million (Q1 2026), $8.0 million (Q4 2025), and $9.0 million (Q3 2025).